UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - CHINOOK THERAPEUTICS INC ownership

CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 2 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ownership history of CHINOOK THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$563,9340.0%24,3600.0%0.00%
Q1 2023$563,934
-36.0%
24,360
-27.5%
0.00%
Q4 2022$880,792
-99.8%
33,618
+17.8%
0.00%
Q3 2022$561,136,000
+112.3%
28,542
+88.9%
0.00%
Q2 2022$264,256,00015,1090.00%
Other shareholders
CHINOOK THERAPEUTICS INC shareholders Q2 2024
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 5,161,888$198,319,73734.81%
Saturn V Capital Management LP 524,811$20,163,23911.18%
Frazier Life Sciences Management, L.P. 4,345,559$166,956,3779.97%
Altium Capital Management LP 305,000$11,718,1008.87%
MPM BioImpact LLC 1,003,406$38,550,8597.76%
Affinity Asset Advisors, LLC 321,017$12,333,4734.31%
ALPINE ASSOCIATES MANAGEMENT INC. 2,131,000$81,873,0203.69%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,748,141$67,163,5773.59%
Nan Fung Group Holdings Ltd 113,950$4,377,9592.80%
Vivo Capital, LLC 934,879$35,918,0512.48%
View complete list of CHINOOK THERAPEUTICS INC shareholders